In fact, a small molecule αVβ1 inhibitor, which was able to down-regulate TGFβ-induced signaling in vivo, showed a significant therapeutic effect in reducing CCl4-induced hepatic fibrosis in mice [98]. Here, TGFB1 is linked to Hepatic fibrosis.